Target Validation Information
TTD ID	T02318
Target Name	B-cell-activating factor (TNFSF13B)
Type of Target	Successful
Drug Potency against Target	Belimumab	Drug Info	EC50 = 560 nM	[1]
Action against Disease Model	Atacicept	Drug Info	Atacicept is a h uMan recombinant fusion protein that comprises the binding portion of a receptor for both BLyS (B-Lymphocyte Stimulator) and APRIL (A PRoliferation-Inducing Ligand), two cytokines that have been identified as important regulators of B-cell maturation, function and survival. Atacicept has shown selective effects on cells of the B-cell lineage, acting on mature B cells and blocking plasma cells and late stages of B-cell development while sparing B-cell progenitors and memory cells. The efficacy of atacicept in animal models of autoimmune disease and the biological activity of atacicept in patients with systemic lupus erythematosus (SLE) and rhe uMatoid arthritis (RA) has been demonstrated.	[2]
References
REF 1	NF-kappaB: the inducible factors of HIV-1 transcription and their inhibitors. Mini Rev Med Chem. 2009 Jan;9(1):60-9.
REF 2	Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord. 2010 Jul;3(4):205-16.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.